Skip to content
NEOVACS logo

NEOVACS Alternatives & Competitors

12 companies similar to NEOVACS — Nous développons les thérapies de demain et investissons dans des sociétés innov...

Companies similar to NEOVACS

Tridek-One logo — alternative to NEOVACS

Tridek-One

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...

AnaptysBio logo — alternative to NEOVACS

AnaptysBio

Transforming patient health by delivering innovative immunology therapeutics.

Novelogics Biotechnology Inc. logo — alternative to NEOVACS

Novelogics Biotechnology Inc.

Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer us...

Antharis Therapeutics, Inc. logo — alternative to NEOVACS

Antharis Therapeutics, Inc.

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...

Rival Readout

Competing with NEOVACS? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
MabGenesis Inc. logo — alternative to NEOVACS

MabGenesis Inc.

Discovery of innovative therapeutic antibodies for human and animal health

United Biomedical, Inc. (UBI) logo — alternative to NEOVACS

United Biomedical, Inc. (UBI)

Pioneering the future of healthcare with innovative immunotherapeutics and vaccines for ch...

Evelo Biosciences logo — alternative to NEOVACS

Evelo Biosciences

Clinical stage biotech company developing a new modality of oral biologics that act on cel...

Precision Biologics, Inc.  logo — alternative to NEOVACS

Precision Biologics, Inc.

Precision Biologics, Inc. has a cancer immunotherapy platform with 2 unique clinical stage...

ImmunGene logo — alternative to NEOVACS

ImmunGene

Innovation in antibody-cytokine fusion technology and monoclonal antibody-based therapies...

Cantargia AB logo — alternative to NEOVACS

Cantargia AB

A Swedish listed biotechnology company

ACM Biolabs logo — alternative to NEOVACS
Tolerx, Inc. logo — alternative to NEOVACS

About NEOVACS

**NEOVACS** NEOVACS is a French Biotechnology company founded in 1993. Their mission is to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases. Additionally, they invest in innovative companies within the Biotech and Medtech industries.

Services

biotechnology research and development, drug development, investing in biotech and medtech companies

Target Customers

patients with lupus and allergies, biotech and medtech companies

Business keywords

Therapeutic Vaccines, Autoimmune Diseases, Inflammatory Diseases, Immunotherapy, Medtech, AIDS Treatment, Cancer Treatment, Polyclonal Antibody Response, Immunologist, Viral Proteins, Monoclonal Antibodies, Cytokine-related Diseases, Allergic Diseases

Frequently Asked Questions

Companies similar to NEOVACS include Tridek-One, AnaptysBio, Novelogics Biotechnology Inc., Antharis Therapeutics, Inc., MabGenesis Inc.. They work in Biotechnology and Health Care and share NEOVACS's focus on cancer treatment, monoclonal antibodies and autoimmune diseases.
Bounce Watch lists 12 companies that share NEOVACS's industries and are closest to it in business tags, services, target customers, business model and size.
**NEOVACS** NEOVACS is a French Biotechnology company founded in 1993. Their mission is to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases. Additionally, they invest in innovative companies within the Biotech and Medtech industries.

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around NEOVACS: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at NEOVACS on 7 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout